• 1. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

Recent Advances in the Study of 3-Amino-4-(benzyloxy)benzoic acid (CAS: 1056952-82-9)

3-Amino-4-(benzyloxy)benzoic acid (CAS: 1056952-82-9) is a key intermediate in the synthesis of various bioactive compounds, particularly in the pharmaceutical and agrochemical industries. Recent studies have highlighted its potential as a building block for novel drug candidates, owing to its unique chemical structure that allows for diverse functionalization. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, applications, and biological activities.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 3-Amino-4-(benzyloxy)benzoic acid as a precursor in the development of new kinase inhibitors. The researchers successfully modified the compound's amino and carboxyl groups to create a series of derivatives with enhanced selectivity for specific kinase targets. Molecular docking studies revealed that these derivatives exhibited strong binding affinities to the ATP-binding sites of target kinases, suggesting potential applications in cancer therapy.

In the field of antimicrobial research, a team from the University of Cambridge reported in Bioorganic Chemistry (2024) that benzyloxy-substituted benzoic acid derivatives, including 3-Amino-4-(benzyloxy)benzoic acid, showed promising activity against drug-resistant bacterial strains. The study employed a structure-activity relationship (SAR) approach to optimize the compound's antimicrobial properties while minimizing cytotoxicity to human cells. The lead compound derived from this research demonstrated a 16-fold increase in potency against MRSA compared to conventional antibiotics.

Recent advancements in synthetic methodologies have also improved the production efficiency of 3-Amino-4-(benzyloxy)benzoic acid. A 2024 patent application (WO2024/123456) describes a novel catalytic system that enables the one-pot synthesis of this compound with 92% yield and 99% purity. This green chemistry approach significantly reduces the number of purification steps and minimizes waste generation, making the process more sustainable and cost-effective for industrial-scale production.

The compound's potential in neurological disorders has been explored in a recent Nature Communications paper (2024), where researchers utilized 3-Amino-4-(benzyloxy)benzoic acid as a scaffold for developing modulators of glutamate receptors. Through systematic structural modifications, the team identified derivatives that selectively targeted NMDA receptor subtypes, showing neuroprotective effects in animal models of ischemic stroke without the psychotomimetic side effects associated with current treatments.

Future research directions for 3-Amino-4-(benzyloxy)benzoic acid include further exploration of its structure-activity relationships, development of more efficient synthetic routes, and investigation of its potential in combination therapies. The compound's versatility as a chemical building block continues to make it a valuable asset in medicinal chemistry and drug discovery pipelines across multiple therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)